Drug Target Review – Publications

Issue #4 2020

The next issue of Drug Target Review goes to press on  24 November 2020 and will feature:

• In-Depth Focuses on: hit-to-lead, COVID-19, upstream bioprocessing and screening
• A focus on the latest advances in vaccines and immunology
• The latest trends in label free research
• And much more…

To receive our latest journal, you can secure your free print and/or digital copy here.

Latest issue

Issue #3 2020

Drug Target Review – Issue 3 2020

This issue includes articles that explore how a next-generation genomics platform can be used for COVID-19 research, the elimination of…

By Drug Target Review

Issue #3 2020

Antibodies In-Depth Focus 2020

Included in this in-depth focus are articles on antibody therapeutics to treat COVID-19, how AAV antibodies can be neutralised, the…

By Drug Target Review

Issue #3 2020

Targets In-Depth Focus 2020

This in-depth focus includes articles on the importance of a novel target to treat M. tuberculosis infections and how recently…

By Drug Target Review

Issue #3 2020

Assays In-Depth Focus 2020

In this In-Depth Focus find articles exploring the roles of key proteins implicated in Alzheimer's disease and a new technology…

By Drug Target Review

Issue #3 2020

NGS In-Depth Focus 2020

In this NGS In-Depth Focus: how next-generation sequencing (NGS) enables rapid detection of viruses and a novel NGS platform advancing…

By Drug Target Review

Issue #3 2020

Application note: Validated quantitation and activity assay of antibody fragment…

This application note by ForteBio explores antibody fragment molecule (Fab) for process development and quality control.

By ForteBio

Issue #3 2020

Expert view: Increasing the efficiency of biologics development: the secret…

Biologics are becoming increasingly important for the treatment of a wide variety of diseases, with more biologics receiving regulatory approval…

By Charles Heffern (Product Manager at NanoTemper Technologies)

Issue #3 2020

Under the microscope: Searching for optimised drugs: combining AI with…

Applying artificial intelligence (AI) to small molecule drug discovery can provide a more rapid and cost‑effective route to discovering drug…

By Martin Redhead (Head of Quantitative Pharmacology at Exscientia)

Issue #3 2020

Expert view: Analytical power tool opens upstream bioprocessing bottlenecks for…

The Octet® systems provide broad applications in high throughput to help bispecific and multi-specific antibody discovery.

By Hongshan Li (Marketing Applications Manager at FortéBio)

Issue #3 2020

Defusing antibody neutralisers in AAV gene therapy

Adeno-associated virus (AAV)-mediated gene therapies allow for the treatment of a growing number of diseases; however, the presence of neutralising…

By Nikki Withers (Drug Target Review)

Issue #3 2020

Antibody therapeutics for COVID-19

In 2019, the SARS-CoV-2 coronavirus sparked a global pandemic that is likely to continue into 2021. Effective therapeutics that treat…

By Dr Janice M Reichert (The Antibody Society)

Issue #3 2020

Oncology meets immunology – antibody-mediated regulation of the immune response

In this article, Aparajita Dubey discusses the role of antibodies in regulating the immune system and highlights key features that…

By Aparajita Dubey (CRAMbridge)

Issue #3 2020

Bispecific antibodies: the next generation of immuno-oncology drugs

Taylor B Guo, Chief Scientific Officer at I-Mab, describes the potential benefits of bispecific antibodies for cancer therapy and how…

By Taylor B Guo (I-Mab)

Issue #3 2020

Expert view: Why you should use 3D models for high-throughput…

The clinical success rate of new oncology drugs is low compared to other diseases. One contributing factor is likely to…

By Horizon Discovery

Issue #3 2020

Expert view: ddPCR whole cell DNA workflow efficiently measures success…

Not every step of CAR T-cell manufacturing can be tightly regulated, introducing some significant quality control challenges for companies developing…

By Bio-Rad Laboratories

Issue #3 2020

Expert view: Where are you seeing changes in the flow…

We have entered a new era of drug discovery where the use of advanced cell models such as multi-cellular co-cultures,…

By Sartorius

Issue #3 2020

Flow cytometry in neglected tropical diseases – a focus on…

The World Health Organization (WHO) identifies leishmaniasis as a neglected tropical disease for which new treatments are vitally needed. Leishmaniasis…

By Professor Paul Kaye (University of York)

Issue #3 2020

Advancing cell therapies with engineered Tregs

Regulatory T cells (Tregs) play a key role in regulating our immune system and inflammatory processes. Sangamo Therapeutics is evaluating…

By Jason Fontenot (Sangamo Therapeutics)

Issue #3 2020

Application note: Accurate affinity profiling of a SARS-CoV-2 antibody in…

In this application note, Fluidic Analytics show that by using MDS on the Fluidity One-W Serum we can accurately detect…

By Fluidic Analytics

Issue #3 2020

Application note: 3D cell panel screens for drug discovery and…

Horizon Discovery have developed their 3D OncoSignature™ spheroid screening service that consists of a panel of 200 cell lines. In…

By Horizon Discovery

Issue #3 2020

Whitepaper: Evaluation of the analytical performance of the AQUIOS CL…

This whitepaper from Beckman Coulter evaluates the analytical performance of the AQUIOS CL flow cytometer in a multi‑centre study.

By Beckman Coulter Inc

Issue #3 2020

Expert view: Measuring protein interactions in blood – not as…

In the continuing battle against COVID-19, researchers now must identify the best candidates for vaccines and convalescent serum therapies against…

By Fluidic Analytics

Issue #3 2020

Under the microscope: Supporting the COVID-19 response with NGS

Responding efficiently to urgent situations is of utmost importance in times of crisis. Dr Suvarna Gandlur, Associate Director of Takara…

By Takara

Issue #3 2020

Under the microscope: Transforming drug discovery on membrane proteins

IN NOVEMBER 2017, leadXpro chose to strengthen its capabilities with the Creoptix™ WAVEsystem. “We were looking for a label‑free, biophysical…

By Creoptix

Issue #3 2020

Powering forward – Genomics England’s COVID-19 response

Genomics England has launched a next-generation genomic research platform that will play a key role in the response to COVID-19.…

By Nikki Withers (Drug Target Review)

Issue #3 2020

NGS: offering a glimmer of hope in the fight against…

Next-generation sequencing (NGS) has become the method of choice for many researchers responding to infectious disease outbreaks and in the…

By Pushpanathan Muthuirulan (Harvard University)

Issue #3 2020

Novel biomarker technology for cancer diagnostics

A new way of identifying cancer biomarkers has been developed by researchers at Lund University in Sweden. The new technology…

By Nikki Withers (Drug Target Review)

Issue #3 2020

Exploring new drug targets in Alzheimer’s disease

Although many potential targets have been identified for Alzheimer’s disease (AD), there is no effective treatment for this debilitating condition.…

By Monika Schmidt (University of Hradec Kralove), Sheraz Gul (Fraunhofer Institute)

Issue #3 2020

Adding to the arsenal: targeting human proteins for controlling M.…

The National Institute of Health envisions a plan for managing tuberculosis in the 21st century. Included in this proposal is…

By Navodita Jain (Syngene International)

Issue #3 2020

Exploring the intra-protein non-covalent interactions in the S1 domain of…

The Spike (S) protein is a promising drug target in the quest to develop vaccines and antivirals for SARS-CoV-2 to…

By Oscar Bastidas (University of Minnesota)

Issue #3 2020

Understanding the limits of synthetic biology through the origins of…

Conspiracy theories about COVID-19 have been spreading since the early days of the outbreak. But how do we know whether…

By Marc Baiget Francesch (International Journal of Molecular Sciences)

Issue #3 2020

COVID-19 therapies in the pipeline

As the global COVID-19 situation is rapidly changing, staying abreast with the latest news can be challenging. In this article,…

By Sheraz Gul (Fraunhofer Institute)

Issue #3 2020

Cocaine and the brain: identifying targets for addiction therapies

There are currently no licenced pharmaceuticals to treat cocaine addiction. To overcome this issue, US researchers at the University of…

By Hannah Balfour (Drug Target Review)

Past Issues

Issue #2 2020

Drug Target Review – Issue 2 2020

Issue #1 2020

Drug Target Review – Issue 1 2020

Issue #4 2019

Drug Target Review – Issue 4 2019

Issue #3 2019

Drug Target Review – Issue 3 2019

Issue #2 2019

Drug Target Review – Issue 2 2019

Issue #1 2019

Drug Target Review – Issue 1 2019

Issue #4 2018

Drug Target Review – Issue 4 2018

Issue #3 2018

Drug Target Review – Issue 3 2018

Issue #2 2018

Drug Target Review – Issue #2 2018

Issue #1 2018

Drug Target Review – Issue #1 2018

Issue #4 2017

Drug Target Review – Issue #4 2017

Issue #3 2017

Drug Target Review – Issue #3 2017

Issue #2 2017

Drug Target Review – Issue #2 2017

Issue #1 2017

Drug Target Review – Issue #1 2017

Issue #4 2016

Drug Target Review – Issue #4 2016

Supplements & Special Editions

Issue #2 2020

Stem Cells In-Depth Focus 2020

Issue #2 2020

Imaging In-Depth Focus 2020

Issue #2 2020

Immuno-oncology In-Depth Focus 2020

Issue #2 2020

Screening In-Depth Focus 2020

Issue #1 2020

Lab Automation In-Depth Focus 2020

Issue #1 2020

Informatics In-Depth Focus 2020

Issue #1 2020

Antibodies In-Depth Focus 2020

Issue #1 2020

Assays In-Depth Focus 2020

Issue #4 2019

Hit-To-Lead In-Depth Focus 2019

Issue #4 2019

Targets In-Depth Focus 2019

Issue #4 2019

Screening In-Depth Focus 2019

Issue #3 2019

Upstream Bioprocessing In-Depth Focus 2019

Issue #3 2019

Antibodies In-Depth Focus 2019

Issue #3 2019

Genomics In-Depth Focus 2019

Issue #2 2019

Screening In-Depth Focus 2019